

## Ascendiant Capital Markets LLC serves as Co-Manager on RedHill Biopharma's \$20,000,000 Public Offering

IRVINE, Calif., December 11, 2018 -- Ascendiant Capital Markets LLC ("Ascendiant") announced today the closing of a \$20,000,000 public offering for RedHill Biopharma Ltd. (NasdaqGM: RDHL) of Tel-Aviv, Israel.

Ascendiant served as a Co-Manager of the offering.

RedHill intends to use the net proceeds from the offering, together with its existing cash and cash equivalents, to fund preparations for TALICIA<sup>®</sup> (H. pylori) commercial launch and commercialization activities, clinical development programs, including initiation of a pivotal Phase 3 study with RHB-204 for NTM, preparations for a second Phase 3 study with RHB-104 for Crohn's disease and for acquisitions and general corporate purposes.

## About RedHill Biopharma Ltd.

RedHill Biopharma Ltd. (NasdaqGM: RDHL) (Tel-Aviv Stock Exchange: RDHL) is a specialty biopharmaceutical company primarily focused on the development and commercialization of late clinical-stage, proprietary drugs for the treatment of gastrointestinal diseases. RedHill commercializes and promotes four gastrointestinal products in the U.S.

## About Ascendiant Capital Markets LLC

Ascendiant Capital Markets, LLC, based in Irvine, California, is a full-service investment banking, equity research, market making, and securities trading firm focused on public and private companies, and institutional, accredited, and strategic investors.

Ascendiant has led or participated in over \$1 billion in financing transactions, and the members of Ascendiant's Investment Banking Team have completed over 300 M&A transactions.

Ascendiant Capital Markets is registered with the United States Securities and Exchange Commission (SEC) as a broker-dealer, and is a member of the FINRA and SIPC.

For more information, please visit www.ascendiant.com or contact Bradley J. Wilhite, Co-Founder & Managing Partner, at 949.259.4949 or bwilhite@ascendiant.com

This press release shall not constitute an offer to sell or the solicitation of an offer to buy the securities described herein, nor shall there be any sale of these securities in any jurisdiction in which such offer, solicitation or sale would be unlawful prior to the registration or qualification under the securities laws of any such jurisdiction.